Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

Rhea-AI Summary

Prometheus Biosciences (Nasdaq: RXDX) will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 12 at 1:30 p.m. EST. Mark McKenna, Chairman and CEO, will provide an overview of the company, which focuses on precision medicine for immune-mediated diseases. The presentation will be available via webcast on Prometheus’ website for 30 days after the event. The company is advancing its lead candidate, PRA023, an IgG1 monoclonal antibody currently in Phase 2 trials for ulcerative colitis and Crohn's disease, with plans for additional trials in systemic sclerosis-associated interstitial lung disease.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40^th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST.

The presentation will be webcast live on the Events & Webcasts page on the Investor section of Prometheus’ website and will be available for 30 days following the presentation. It is recommended that users connect to Prometheus’ website several minutes prior to the start of the webcast to ensure a timely connection.

About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360™, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of immune-mediated diseases including Ulcerative colitis (UC), Crohn’s disease (CD), and the newly identified systemic sclerosis-associated interstitial lung disease (SSc-ILD). The Company is currently conducting a Phase 2 trial in UC patients and a Phase 2a trial in CD patients, each utilizing a proprietary genetic-based companion diagnostic designed to identify patients who are predisposed to increased expression of TL1A and therefore potentially more likely to respond to PRA023. The company also plans to initiate a Phase 2 clinical trial for PRA023 in SSc-ILD in the first quarter of 2022.

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com

FAQ

What is Prometheus Biosciences presenting at the J.P. Morgan Healthcare Conference on January 12, 2022?

Prometheus Biosciences will provide a company overview presentation at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2022, at 1:30 p.m. EST.

Who is presenting for Prometheus Biosciences at the conference?

Mark McKenna, Chairman and CEO of Prometheus Biosciences, will present at the conference.

How can I access the presentation by Prometheus Biosciences?

The presentation will be webcast live on Prometheus’ Events & Webcasts page and available for 30 days.

What is the focus of Prometheus Biosciences' research?

Prometheus Biosciences specializes in precision medicine for immune-mediated diseases, developing novel therapeutic and companion diagnostic products.

What is PRA023 and its significance for Prometheus Biosciences?

PRA023 is Prometheus’ lead candidate, an IgG1 monoclonal antibody targeting immune-mediated diseases like ulcerative colitis and Crohn's disease, currently in Phase 2 trials.